Phase 2 open-label RCT in 83 adults with HTLV-1: dolutegravir vs vitamin C for 48 weeks did not change the primary outcome, 10-metre walk time; as a key secondary outcome, dolutegravir lowered proviral load (P<.001).
RCTn = 83
Brites et al. Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial